Isoglycyrrhizinate

Drug Profile

Isoglycyrrhizinate

Alternative Names: 2005S07127; Ganmei; Magnesium isoglycyrrhizinate; Tianqing Ganmei; Tianqingganmei; Yigancaosuanmei Zhusheye

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Chia Tai Tianqing Pharmaceutical Group
  • Developer Chia Tai Tianqing Pharmaceutical Group; Shanghai Jiao Tong University
  • Class Anti-inflammatories; Saponins
  • Mechanism of Action Antioxidants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Chronic hepatitis; Liver disorders

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Liver-disorders(In volunteers) in China (IV, Infusion)
  • 14 Apr 2016 Launched for Liver disorders and Chronic hepatitis in China (IV) before April 2016 (Chia Tai Tianqing Pharmaceutical Group website, April 2016)
  • 14 Apr 2016 Adverse events data from a phase III trial in Liver disorders released by Chia Tai Tianqing Pharmaceutical Group (IV, Injection) (Chia Tai Tianqing Pharmaceutical Group website, April 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top